Shaperon Is A Clinical Stagebiotech Company Developing Novel Inflammasomeinhibitors Small Moleculeits Uniquemechanism Of Action Of Gpcr Regulated P2X7 Inhibition Suppresses A Broad Spectrum Of Inflammatory Cytokines Including Il 1I Il 18Il 6And Tnf I Etcby Controlling Both Priming And Activation Phaseof Inflammasomewhereas Conventional Approaches Aredesigned To Suppress Only Theactivation Phasewith This Uniqueand Novel Modality Which Is Best Suited To Address Complex Immunemediated Inflammatory Disorderswearecurrently Developing Multipleclinical Programs In Atopic Dermatitiscytokinereleasesyndromealzheimer S Diseaseulcerativecolitisnashetc In Addition To Inflammasomer&D Programsshaperon Has Anti Viralanti Cancer Nanobody Therapeuticsshaperon S Proprietary Immunized Nanobody Libraries Combined With High Throughput Screening And In Vitro In Vivo System Enableus To Fast Forward Therealization Of Advantages Of Nanobodies Over Conventional Antibody Based Medicineswecurrently Developing Multi Valentmulti Specific Nanobodies In Multipledelivery Forms In Oncology And Viral Infection Diseases
United States
